Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan-Dec:22:15347354231159322.
doi: 10.1177/15347354231159322.

A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models

Shaunak K Pandya  1 , Arati Pandya  2 , Ashley Larsen  1 , Krisstina Gowin  1
Affiliations
Review

A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models

Shaunak K Pandya et al. Integr Cancer Ther. 2023 Jan-Dec.

Abstract

Proteasome inhibitors are the cornerstone of multiple myeloma treatment, but challenges still remain despite the increased survival rates. We conducted a review on the role of curcumin, a natural product, as an adjunct to bortezomib and carfilzomib in preclinical multiple myeloma models. Four studies reviewed showed enhanced anticancer effects when curcumin was combined with bortezomib compared to either treatment alone. Two additional studies showed similar results with carfilzomib. Synergistic mechanisms include inhibition of NF-kB, IL-6-induced signaling pathways, JNK pathway modulation, and increased cell cycle arrest.

Keywords: bortezomib; carfilzomib; curcumin; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Flow diagram outlining the literature review and study retrieval.
Figure 2.
Figure 2.
Synergistic effects of curcumin and proteasome inhibitors on pathways involved in MM cells.
Figure 3.
Figure 3.
Synergism of proteasome inhibitors and curcumin.
See this image and copyright information in PMC

References

    1. Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. doi: 10.1038/nrdp.2017.46 - DOI - PubMed
    1. Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 2018;4(9):1221-1227. doi: 10.1001/jamaoncol.2018.2128 - DOI - PMC - PubMed
    1. Ito S. Proteasome inhibitors for the treatment of multiple myeloma. Cancers. 2020;12(2):265. doi: 10.3390/cancers12020265 - DOI - PMC - PubMed
    1. Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017;14(7):417-433. doi: 10.1038/nrclinonc.2016.206 - DOI - PMC - PubMed
    1. Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochem Pharmacol. 2015;96(1):1-9. doi: 10.1016/j.bcp.2015.04.008 - DOI - PubMed

MeSH terms